Brief: Rein Therapeutics Doses First Patient In Phase 2 Trial Of Lti-03 For Idiopathic Pulmonary Fibrosis
03/03/2026 13:01
March 3 (Reuters) - Rein Therapeutics Inc RNTX.O: REIN THERAPEUTICS DOSES FIRST PATIENT IN PHASE 2 TRIAL OF LTI-03 FOR IDIOPATHIC PULMONARY FIBROSIS Source text: ID:nGNX54mPpq Further company coverage: RNTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering